Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas

SUPPLEMENTARY MATERIALS

Supplementary Table 1: Cell lines characteristics and Trop2 expression

| CELL LINE | AGE | RACE | FIGO* STAGE | PRIMARY SITE | HISTOLOGY       | TROP2 MFI | SCORE |
|-----------|-----|------|-------------|--------------|-----------------|-----------|-------|
| SARARK1   | 70  | A    | IC          | Uterus       | END-CC Homologous ESS | 20,5      | 1+    |
| SARARK3   | 74  | W    | IIIC        | Ovary        | SER Heterologous CDRS | 437,4     | 2+    |
| SARARK4   | 77  | W    | IIIC        | Ovary        | SER Heterologous CDRS | 201,9     | 2+    |
| SARARK7   | 55  | W    | IV          | Ovary        | CC-SER Heterologous CDRS | 0,5       | 0     |
| SARARK9   | 66  | W    | IIIC2+      | Uterus       | SER Homologous ESS | 271,4     | 2+    |
| SARARK11  | 67  | W    | IIIC1       | Uterus       | END Heterologous CDRS | 15,1      | 0     |
| SARARK12  | 39  | W    | IVB         | Uterus       | SER Homologous ESS | 5,3       | 0     |
| SARARK13  | 72  | W    | IVB         | Uterus       | SER Heterologous CDRS | 7,2       | 0     |
| SARARK14  | 59  | B    | IVB         | Uterus       | SER END Homologous ESS | 5,9       | 0     |

Abbreviations: *FIGO, International Federation of Gynecology and Obstetrics; CC, clear cell; CDR, chondroid; CDRS, chondrosarcoma; EC, epithelial component; END, endometrioid; ESS, endometrial stromal sarcoma; MFI, mean fluorescence intensity; SC, sarcomatous component; SER, serous.